Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-d… Read more
Lyka Labs Limited (LYKALABS) - Total Liabilities
Latest total liabilities as of September 2025: ₹664.32 Million INR
Based on the latest financial reports, Lyka Labs Limited (LYKALABS) has total liabilities worth ₹664.32 Million INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lyka Labs Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Lyka Labs Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lyka Labs Limited Competitors by Total Liabilities
The table below lists competitors of Lyka Labs Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atlantic Sapphire ASA
OTCQB:AASZF
|
USA | $82.17 Million |
|
Power & Instrumental (Gujarat) Limited
NSE:PIGL
|
India | ₹866.35 Million |
|
J.R.W. Utility Public Company Limited
BK:JR
|
Thailand | ฿2.29 Billion |
|
Dome Gold Mines Ltd
AU:DME
|
Australia | AU$751.02K |
|
Imago Mulia Persada Tbk PT
JK:LFLO
|
Indonesia | Rp89.24 Billion |
|
Silla Textile Co.Ltd
KQ:001000
|
Korea | ₩16.64 Billion |
|
Wiseway Group Ltd
AU:WWG
|
Australia | AU$64.78 Million |
|
Softing AG
XETRA:SYT
|
Germany | €50.60 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Lyka Labs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lyka Labs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lyka Labs Limited (2005–2025)
The table below shows the annual total liabilities of Lyka Labs Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹726.24 Million | -17.90% |
| 2024-03-31 | ₹884.59 Million | -16.43% |
| 2023-03-31 | ₹1.06 Billion | -38.50% |
| 2022-03-31 | ₹1.72 Billion | -19.98% |
| 2021-03-31 | ₹2.15 Billion | -0.08% |
| 2020-03-31 | ₹2.15 Billion | +25.45% |
| 2019-03-31 | ₹1.72 Billion | -2.96% |
| 2018-03-31 | ₹1.77 Billion | -14.29% |
| 2017-03-31 | ₹2.06 Billion | +7.21% |
| 2016-03-31 | ₹1.92 Billion | -17.11% |
| 2015-03-31 | ₹2.32 Billion | -15.03% |
| 2014-03-31 | ₹2.73 Billion | +24.69% |
| 2013-03-31 | ₹2.19 Billion | +5.89% |
| 2012-03-31 | ₹2.07 Billion | -2.98% |
| 2010-03-31 | ₹2.13 Billion | +19.17% |
| 2009-03-31 | ₹1.79 Billion | +68.57% |
| 2008-03-31 | ₹1.06 Billion | -6.54% |
| 2007-03-31 | ₹1.14 Billion | +1.66% |
| 2005-03-31 | ₹1.12 Billion | -- |